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Delayed time to chemotherapy (TTC) is associated with decreased outcomes of breast cancer patients. Recently, studies
suggested that the association might be subtype-dependent and that TTC within 30 days should be warranted in patients with
triple-negative breast cancer (TNBC). The aim of the current study is to determine if TTC beyond 30 days is associated with
reduced 10-year overall survival in TNBC patients. We identiﬁed all TNBC patients diagnosed between 2006 and 2014 who
received adjuvant chemotherapy in the Netherlands. We distinguished between breast-conserving surgery (BCS) vs.
mastectomy given the difference in preoperative characteristics and outcomes. The association was estimated with hazard
ratios (HRs) using propensity-score matched Cox proportional hazard analyses. In total, 3,016 patients were included. In
matched patients who underwent BCS (n = 904), 10-year overall survival was favorable for patients with TTC within 30 days
(84.4% vs. 76.9%, p = 0.001). Patients with TTC beyond 30 days were more likely than those with TTC within 30 days to die
within 10 years after surgery (HR 1.69 (95% CI 1.22–2.34), p = 0.002). In matched patients who underwent mastectomy
(n = 1,568), there was no difference in 10 years overall survival between those with TTC within or beyond 30 days (74.5% vs.
74.7%, p = 0.716), nor an increased risk of death for those with TTC beyond 30 days (HR 1.04 (95% CI 0.84–1.28), p = 0.716).
Initiation of adjuvant chemotherapy beyond 30 days is associated with decreased 10 years overall survival in TNBC patients
who underwent BCS. Therefore, timelier initiation of chemotherapy in TNBC patients undergoing BCS seems warranted.
Introduction
Breast cancer is the most commonly diagnosed cancer and
has the second-highest mortality rate among women.1 Patients
diagnosed with high-risk tumors such as triple-negative breast
cancer (TNBC) have an adverse prognosis compared to
patients with other subtypes.2 For these patients, locoregional
treatment consists of breast-conserving surgery (BCS) with
radiation therapy or mastectomy with or without radiation
therapy. Adjuvant chemotherapy is standard of care for
patients with TNBC.3,4 as the treatment reduces the risk on a
distant recurrence and improves overall survival.5,6
Although an optimal interval from surgery to adjuvant che-
motherapy (Time to Chemotherapy, TTC) is not precisely
deﬁned, guidelines recommend to initiate chemotherapy within
6–12 weeks after surgery.7,8 Several studies showed an association
between delayed initiation of chemotherapy and worse breast
cancer outcomes, though with different cut-off points between
6 and 12 weeks.9–12 Although patients with TNBC are less likely
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to have delayed TTC compared to other subtypes,13–16 between
35% and 74% of patients with TNBC receive adjuvant chemo-
therapy beyond 30 days after surgery.9,10,16–18
In the recent years, several studies have suggested that the
impact of TTC on survival might be subtype-dependent and
that initiation of adjuvant chemotherapy within 30 days could
be warranted particularly in patients with high-risk breast
cancer such as TNBC,9,10,17,18 as this type has a more aggres-
sive biology and rapid proliferation rate compared to other
subtypes.19 However, the current evidence that a TTC within
30 days is warranted in patients with TNBC is based on
single-center studies with weak methodology.11 None of the
previous studies stratiﬁed analyses for the type of surgery or
adjusted for confounding by indication by matching patients
on the likelihood to receive adjuvant chemotherapy within
30 days. This latter is crucial as patients with certain baseline
characteristics, such as old age, use of breast reconstruction or
hospital transfer, do not have the same chance of TTC within
30 days so that it is not clear whether it is the TTC or the
underlying indication causing the reduced survival.9,15,20 Fur-
thermore, it is not always clear if previous studies excluded
patients who received adjuvant radiation therapy before
chemotherapy.
In the current study, we conducted a propensity score-
matched analysis in a prospective, population-based cohort to
assess the extent to which TTC beyond 30 days is associated
with survival among patients diagnosed with TNBC. To fur-
ther limit confounding by indication, we focused only on
patients who underwent surgery followed by chemotherapy
and stratiﬁed the analyses by type of surgery.
Methods
Data were anonymously obtained from the Netherlands Can-
cer Registry (NCR). The NCR is a prospective nationwide reg-
ister for all malignancies diagnosed in all hospitals in the
Netherlands. Based on notiﬁcation from the Pathology
Archive (PALGA) it includes patient, tumor and treatment
characteristics, which are registered by trained data managers.
Vital status is regularly obtained in the NCR database through
linkages with the municipality register. Our study has been
approved by the privacy committee of the NCR.
All women diagnosed with Stage I–III TNBC between 2006
and 2014 who underwent breast-conserving surgery (BCS) or
a mastectomy were selected. The hormonal receptors were
categorized as negative when <10% of tumor cells were posi-
tively stained following the Dutch Breast Cancer guidelines.
Human Epidermal growth factor Receptor (HER) 2 was
deﬁned negative in case of protein overexpression in an
immunohistochemistry test or gene ampliﬁcation in a ﬂuores-
cence in situ hybridization test. TNBC was deﬁned when
estrogen-negative, progesterone-negative and HER2-negative.
For the current study, only TNBC patients who received adju-
vant chemotherapy were selected. We excluded patients who
were treated with radiotherapy before chemotherapy, as the
current study focused on impact of delayed TTC and part of
the delay could otherwise be due to delay in or recovery from
radiotherapy. Furthermore, we excluded patients diagnosed
with metachronous primary breast cancers, metastatic disease,
treatment with neoadjuvant chemotherapy, unknown date of
operation or start of chemotherapy as this makes calculation
of TTC impossible. Patients with extreme TTCs beyond
6 months were also excluded as these were most likely data
entry errors.
All patients received adjuvant chemotherapy according to
the Dutch Breast Cancer Guidelines applicable at that point in
time. Alterations to the guidelines were made in 2008 and
2012 which is shown in Supporting Information Table S1.
Every treatment schedule contained an Anthracycline. Since
2008 additionally a taxane was included for high-risk patients.
Since baseline characteristics and breast cancer outcomes
differ between the different types of surgery, patients were cat-
egorized into (i) patients who underwent BCS and (ii) patients
who underwent mastectomy. The type of surgery was deﬁned
by the deﬁnitive surgery performed. TTC was deﬁned as the
number of days between deﬁnitive breast surgery and initia-
tion of adjuvant chemotherapy. Type or moment of axillary
surgery was not taken into account. Within each patient
group, patients were categorized into two-time interval
groups; TTC ≤30 days and TTC >30 days. The primary out-
come of our study was 10-year overall survival, which was
deﬁned as time from deﬁnitive surgery until last contact, being
the date of death or last linkage of the NCR with the munici-
pality register. The last linkage for the current study was on
February 1, 2018.
To limit confounding by indication, a propensity score was
created for having TTC beyond 30 days using a logistic regres-
sion model.21 The following covariates were included in the
propensity score; year of diagnosis, age, socioeconomic status
What’s new?
Current breast cancer treatment guidelines recommend that chemotherapy is initiated between 6-12 weeks after surgery.
Delayed treatment can lead to poorer outcome, but there’s no precise deﬁnition of the optimal window. Recent work suggests
that for patients with triple negative breast cancer (TNBC), it’s best to initiate chemotherapy within 30 days. Here, the authors
evaluated outcomes for TNBC patients correlated with time to chemotherapy. They found that in patients undergoing breast-
conserving surgery, an interval of more than 30 days before chemotherapy was associated with decreased survival. If the
patient had undergone a mastectomy, a longer delay before chemotherapy did not impact survival.
2 Timelier initiation of chemotherapy in TNBC patients
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(SES), histological tumor type, differentiation grade, stage, re-
excision and change of hospital after surgery. Patients were
matched on having the same propensity for TTC > 30 days
using a matching ratio of 1:1.22 The caliper width used in our
analyses was 0.2 times the standard deviation of the logit of
the propensity score. We checked for possible imbalance in
baseline characteristics before and after matching using stan-
dardized differences. A standardized difference of a variable of
≥10% indicates an imbalance in baseline characteristics
between the time interval groups.23 Median follow-up was
determined using the reverse Kaplan–Meier method.24 The
10-year overall survival was estimated using the Kaplan–Meier
Table 1. Comparison of baseline characteristics of patients who underwent breast-conserving surgery according to time to chemotherapy
≤30 days and >30 days before and after matching
Before matching (n = 1,079) After matching (n = 904)
≤30 days
(n = 485)
>30 days
(n = 594)
Standardized
difference
≤30 days
(n = 452)
>30 days
(n = 452)
Standardized
difference
Year of inclusion
2006 32 (6.6) 51 (8.6) 0.075 31 (6.9) 27 (6.0) 0.036
2007 31 (6.4) 42 (7.1) 0.027 31 (6.9) 36 (8.0) 0.042
2008 55 (11.3) 69 (11.6) 0.009 54 (11.9) 59 (13.1) 0.033
2009 51 (10.5) 71 (12.0) 0.046 51 (11.3) 54 (11.9) 0.021
2010 57 (11.8) 106 (17.9) 0.172 57 (12.6) 37 (8.2) 0.145
2011 68 (14.0) 74 (12.5) 0.046 67 (14.8) 71 (15.7) 0.025
2012 70 (14.4) 69 (11.6) 0.084 63 (13.9) 67 (14.8) 0.025
2013 48 (9.9) 64 (10.8) 0.029 48 (10.6) 54 (11.9) 0.042
2014 73 (15.1) 48 (8.1) 0.219 50 (11.1) 47 (10.4) 0.021
Age (years)
<40 79 (16.3) 93 (15.7) 0.017 77 (17.0) 78 (17.3) 0.006
40–49 157 (32.4) 147 (24.8) 0.169 138 (30.5) 141 (31.2) 0.014
50–59 134 (27.6) 198 (33.3) 0.124 131 (29.0) 125 (27.7) 0.029
60–69 101 (20.8) 140 (23.6) 0.066 93 (20.6) 94 (20.8) 0.005
≥70 14 (2.9) 16 (2.7) 0.012 13 (2.9) 14 (3.1) 0.013
SES
Low 149 (30.7) 183 (30.8) 0.002 139 (30.8) 134 (29.6) 0.024
Medium 167 (34.4) 199 (33.5) 0.020 156 (34.5) 157 (34.7) 0.005
High 169 (34.9) 212 (35.7) 0.018 157 (34.7) 161 (35.6) 0.029
Histological tumor type
Ductal 436 (89.9) 544 (91.6) 0.058 410 (90.7) 407 (90.0) 0.023
Lobular 6 (1.2) 6 (0.8) 0.039 3 (0.7) 4 (0.9) 0.025
Other 43 (8.9) 45 (7.6) 0.047 39 (8.6) 41 (9.1) 0.016
Differentiation grade
Well 3 (0.6) 6 (1.0) 0.044 3 (0.7) 2 (0.4) 0.030
Intermediate 58 (12.0) 65 (10.9) 0.032 48 (10.6) 53 (11.7) 0.035
Poor 419 (86.4) 505 (85.0) 0.039 396 (87.6) 395 (87.4) 0.007
Unknown 5 (1.0) 18 (3.0) 0.142 5 (1.1) 2 (0.4) 0.076
Stage
I 136 (28.0) 193 (32.5) 0.096 134 (29.6) 124 (27.4) 0.049
II 286 (59.0) 312 (52.5) 0.130 259 (57.3) 266 (58.8) 0.031
III 63 (13.0) 89 (15.0) 0.058 59 (13.1) 62 (13.7) 0.019
Re-excision
Yes 33 (6.8) 27 (4.6) 0.098 22 (4.9) 24 (5.3) 0.020
Change in hospital
Yes 154 (31.8) 217 (36.5) 0.101 146 (32.3) 136 (30.1) 0.048
Note: Values are numbers (percentages) unless stated otherwise. Percentages may not add up to exactly 100% as a result of rounding.
A standardized difference of a variable of ≥10% is presented in bold. This indicates an imbalance in baseline characteristics between the time interval groups.
Abbreviations: SD, standard deviation; SES, socioeconomic status.
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method and compared between the matched time interval
groups using the log-rank test. The hazard ratios (HR) with
95% conﬁdence intervals (CIs) for occurrence of death were
determined using a Cox regression model in matched patients.
We tested the proportionality assumption using log–log plots
and Schoenfeld residuals which were all satisﬁed. To minimize
the impact of radiotherapy after chemotherapy, subsequent
analyses were conducted with patients who did and did not
Table 2. Comparison of baseline characteristics of patients who underwent mastectomy according to time from surgery to chemotherapy
≤30 days and >30 days before and after matching
Before matching (n = 1937) After matching (n = 1,568)
≤30 days
(n = 806)
>30 days
(n = 1,131)
Standardized
difference
≤30 days
(n = 784)
>30 days
(n = 784)
Standardized
difference
Year of inclusion
2006 60 (7.4) 83 (7.3) 0.004 60 (7.7) 68 (8.7) 0.037
2007 71 (8.8) 101 (8.9) 0.004 69 (8.8) 77 (9.8) 0.035
2008 66 (8.2) 129 (11.4) 0.108 66 (8.4) 33 (4.2) 0.174
2009 89 (11.0) 144 (12.7) 0.052 89 (11.4) 91 (11.6) 0.008
2010 98 (12.2) 160 (14.1) 0.059 96 (12.2) 87 (11.1) 0.036
2011 118 (14.6) 151 (13.4) 0.037 116 (14.8) 120 (15.3) 0.014
2012 111 (13.8) 148 (13.1) 0.020 109 (13.9) 123 (15.7) 0.050
2013 112 (13.9) 113 (10.0) 0.121 104 (13.3) 104 (13.3) 0.000
2014 81 (10.0) 102 (9.0) 0.035 75 (9.6) 81 (10.3) 0.026
Age (years)
<40 216 (26.8) 214 (18.9) 0.188 199 (25.4) 206 (26.3) 0.020
40–49 195 (24.2) 277 (24.5) 0.007 193 (24.6) 206 (26.3) 0.038
50–59 196 (24.3) 280 (24.8) 0.010 193 (24.6) 215 (27.4) 0.064
60–69 172 (21.3) 283 (25.0) 0.087 172 (21.9) 153 (19.5) 0.060
≥70 27 (3.3) 77 (6.8) 0.158 27 (3.4) 4 (0.5) 0.212
SES
Low 263 (32.6) 256 (31.5) 0.025 255 (32.5) 262 (33.4) 0.019
Medium 276 (34.2) 378 (33.4) 0.017 271 (34.6) 272 (34.7) 0.003
High 267 (33.1) 397 (35.1) 0.042 258 (32.9) 250 (31.9) 0.022
Histological tumor type
Ductal 722 (89.6) 1,034 (91.4) 0.063 705 (89.9) 702 (89.5) 0.013
Lobular 20 (2.5) 20 (1.8) 0.049 20 (2.6) 18 (2.3) 0.017
Other 64 (7.9) 77 (6.8) 0.043 59 (7.5) 64 (8.2) 0.024
Differentiation grade
Well 6 (0.7) 10 (0.9) 0.016 6 (0.8) 4 (0.5) 0.032
Intermediate 113 (14.0) 143 (12.6) 0.040 109 (13.9) 118 (15.1) 0.033
Poor 672 (83.4) 960 (84.9) 0.041 656 (83.7) 649 (82.8) 0.024
Unknown 15 (1.9) 18 (1.6) 0.021 13 (1.7) 13 (1.7) 0.000
Stage
I 185 (23.0) 307 (27.1) 0.097 182 (23.2) 173 (22.1) 0.027
II 467 (57.9) 616 (54.5) 0.070 453 (57.8) 466 (59.4) 0.034
III 154 (19.1) 208 (18.4) 0.018 149 (19.0) 145 (18.5) 0.013
Re-excision
Yes 69 (8.6) 73 (6.5) 0.080 63 (8.0) 67 (8.5) 0.019
Change of hospital
Yes 269 (33.4) 413 (36.5) 0.066 267 (34.1) 261 (33.3) 0.016
IBR
Yes 93 (11.5) 146 (12.9) 0.042 93 (11.9) 90 (11.5) 0.012
Note: Values are numbers (percentages) unless stated otherwise. Percentages may not add up to exactly 100% as a result of rounding.
A standardized difference of a variable of ≥10% is presented in bold. This indicates an imbalance in baseline characteristics between the time interval groups.
Abbreviations: IBR, immediate breast reconstruction; SES, socioeconomic status.
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receive radiation therapy. All analyses were performed in
STATA® version 14.2 (StataCorp LLC, College Station, TX).
Data availability
Data can be made available upon reasonable request to the
NCR (data application number K18.145).
Results
The analyses included 3,016 patients, of whom 1,079 (35.8%)
underwent BCS and 1,937 (64.2%) underwent mastectomy.
The mean (standard deviation) age was 51.1 (10.7) and 50.9
(12.4) years at diagnosis for patients who underwent BCS and
mastectomy, respectively.
Of the 1,079 patients who underwent BCS before matching,
485 (45.0%) patients received adjuvant chemotherapy ≤30 days
and 594 (55.1%) patients >30 days. Before matching, the abso-
lute standardized difference was more than 10% in seven cate-
gories of baseline characteristics, suggesting an inadequate
balance (Table 1). In total, 452 (50.0%) patients with TTC
>30 days were successfully matched to 452 (50.0%) patients
with TTC ≤30 days. In these patients, absolute standardized
differences for the covariates, except the year of inclusion 2010,
were <10%, suggesting an overall adequate balance across the
two TTC groups. For matched patients who underwent BCS
within and beyond 30 days, median (interquartile range) TTC
was 26 (22–28) days and 43 (35–72) days, respectively.
Of the 1937 patients who underwent mastectomy, 806 (41.6%)
patients received adjuvant chemotherapy ≤30 days and 1,131
(58.4%) patients >30 days after mastectomy. Before matching,
patients showed a signiﬁcant imbalance in four categories of base-
line characteristics (Table 2). In total, 784 (50.0%) patients with
TTC >30 days were successfully matched to 784 (50.0%) patients
with TTC ≤30 days. After matching, imbalance in two groups
remained (year of inclusion 2008 and age beyond 70). For matched
patients who underwent mastectomy within and beyond 30 days,
median (interquartile range) TTC was 26 (22–28) days and
38 (34–47) days, respectively. All subsequent analyses were per-
formed in thematched patient populations.
Median follow-up was 82.9 (95% CI: 80.5–86.5) and 81.4
(95% CI: 79.5–83.9) months for patients who underwent BCS
and mastectomy, respectively. During the study period,
157 (17.2%) of the BCS matched patients died. In these matched
patients undergoing BCS, 10-year overall survival was signiﬁ-
cantly better in patients with TTC ≤30 days compared to patients
with TTC > 30 days (84.4% [95% CI 79.7–88.1] vs. 76.9% [95%
CI 72.2–81.0], p = 0.001) as shown in Figure 1. Patients with TTC
>30 days were more likely than those with TTC ≤30 days to die
within 10 years after surgery (HR 1.69 (95% CI 1.22–2.34),
p = 0.002). During the study period, 349 (22.3%) of the mastec-
tomy matched patients died. In matched patients undergoing
mastectomy, 10-year overall survival was similar between patients
with TTC ≤30 days and patients with TTC > 30 days (74.5%
[95% CI 70.6–77.9] vs. 74.7% [95% CI 70.9–78.1], p = 0.716) as
shown in Figure 2. Patients with TTC >30 days had the same like-
lihood as patients with TTC ≤30 days to die within 10 years after
surgery (HR 1.04 [95% CI 0.84–1.28], p = 0.716).
A small number of patients who underwent BCS did not
receive radiotherapy after chemotherapy (n = 53). To limit the
Figure 1. Ten-years overall survival for matched patients who underwent breast-conserving surgery with time from surgery to chemotherapy
≤30 days and >30 days. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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potential impact of the use of radiotherapy after chemotherapy
on overall survival, subsequent analyses were performed in BCS
matched patients who received radiotherapy (n = 880). In this
subgroup, the increased likelihood to die within 10 years associ-
ated with TTC > 30 days remained (HR 1.58 [95% CI 1.13–2.22],
p = 0.008). In patients who underwent mastectomy, 1,461
(75.4%) patients did not receive radiotherapy after chemotherapy.
In the subgroup analyses of patients who did not receive radio-
therapy (n = 1,128), patients with TTC > 30 days had a similar
10-year overall survival compared to patients with TTC ≤30 days
(HR 1.10 [95% CI 0.83–1.47], p = 0.500). The same was found in
matched patients who did receive radiotherapy after chemother-
apy (n = 342, HR 0.98 [95% CI 0.70–1.39], p = 0.930).
Discussion
In this population-based cohort study, we demonstrated that
in propensity-score matched patients diagnosed with TNBC
who underwent BCS with TTC beyond 30 days was associated
with a signiﬁcantly increased risk of death compared to those
with a TTC within 30 days, while a TTC beyond 30 days had
no impact on survival for patients undergoing a mastectomy.
Furthermore, we demonstrated that this association was inde-
pendent of the use of adjuvant radiotherapy after chemother-
apy. These results suggest timelier initiation of chemotherapy
in TNBC patients is warranted after BCS, which is relevant
because previous studies showed delay beyond 30 days to
occur in a substantial proportion of these patients.
Even though current literature does not clearly state the opti-
mal timing for adjuvant chemotherapy for all patients, consensus
exists on a more aggressive treatment for TNBC as it has a more
aggressive biology and rapid proliferation rate compared to other
subtypes.4,8,19 Therefore, it makes sense that timely adjuvant che-
motherapy is particularly relevant for these patients. Adjuvant
chemotherapy improves breast cancer outcomes especially by the
cytotoxic effects on micrometastases. Possible explanations for the
decrease in overall survival in patients with delayed TTC include
increased angiogenesis in the tumor and growth of distant micro-
metastases, given that TNBC is characterized by rapid growth
which is now given more time due to delay in TTC.19 The current
study adds to the current evidence that the association is only pre-
sent in patients who underwent BCS and not in those who under-
went mastectomy, as previous studies did not stratify analyses for
type of surgery.11 It is possible that the impact on survival after
BCS is due to patient selection. Patients preference for BCS and
less signiﬁcant surgery can be related to comorbidity or frailty as
well as be the reason for delayed TTC, which independently may
impact patients’ survival.25 This might also explain a smaller
impact on survival in patients who underwent mastectomy as
these patients are known to have more comorbidities compared
to those who underwent BCS.25 Unfortunately, comorbidities and
frailty measures are not registered in the NCR-database and could
therefore not be included in the current study.
Another explanation for the different association of TTC and
overall survival between the two surgical procedures may be
found in the different range of TTC among patients who under-
went BCS with TTC beyond 30 days (median 43 days, inter-
quartile range 35–72 days) compared to those who underwent
mastectomy with TTC beyond 30 days (median 38 days,
Figure 2. Ten-years overall survival for matched patients who underwent mastectomywith time from surgery to chemotherapy ≤30 days and
>30 days. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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interquartile range 34–47 days). However, subsequent multivari-
able analyses categorizing patients into three-time interval
groups showed that both patients who underwent mastectomy
with TTC between 31 and 60 days and beyond 60 days had a
similar survival compared to those with TTC within 30 days
(data not shown), despite the small number of patients with
TTC beyond 60 days (n = 121).
Most previous studies reported an association between del-
ayed TTC in TNBC patients and adverse outcomes.11 Two stud-
ies reported an average 26% signiﬁcantly increased risk of death
in patients with TNBC who have TTC between 31 and 60 days
compared to those with TCC within 30 days.9,10 More recently,
Yu et al. reported in a subgroup analyses (n = 270) that TNBC
patients who had TTC beyond 8 weeks have a worse OS
(HR 2.55, 95% CI 1.25–5.18).18 Unfortunately, these three studies
did not stratify analyses for the type of deﬁnitive surgery nor per-
formed subgroup analyses for use of radiotherapy. The observed
association in these three studies might thus be biased due to dif-
ference in prognosis between provided treatment or due to insuf-
ﬁciently adjusting for unbalanced baseline characteristics. In the
current study, an imbalance in baseline characteristics was seen
before matching between patients who received adjuvant chemo-
therapy within and beyond 30 days. These characteristics could
also be underlying indications for timelier initiation of chemo-
therapy. Poor prognostic characteristics such as older age, higher
differentiation grade, triple-negative receptor status and lymph
node involvement are associated with reduced TTC in many pre-
vious studies, despite using different time thresholds. Since these
poor prognostic characteristics inﬂuence both the indication for
timelier initiation as well as the outcome, estimating a reliable
effect of TTC on survival as performed in our study demanded
adjustment for this confounding by indication. Still, we
cannot rule out residual confounding by unmeasured factors
(i.e., comorbidity of dose-intensity of chemotherapy).
In contrast with the previously mentioned studies, a recent
propensity score-matched single-center study in 724 TNBC
patients observed no difference in disease-free survival and over-
all survival between patients who had TTC within 30, 32–42,
43–56 or beyond 56 days.26 The difference in results with the
current study might be due to the smaller sample size or absence
of stratiﬁed analyses for type of surgery. Moreover, the single-
center setting decreases the generalizability of the former results
due to local clinical practice.
Most previous studies did not specify if adjuvant chemo-
therapy was initiated before or after radiotherapy.11 The
exclusion of patients who received radiotherapy before che-
motherapy in the current study is essential to obtain reliable
results, as there is a signiﬁcant difference in baseline charac-
teristics and breast cancer outcomes between those who
receive chemotherapy before or after radiotherapy.27
In high-income countries, today’s tendency is to give chemo-
therapy in the neoadjuvant setting, thus before surgery, speciﬁ-
cally for patients with locally advanced breast cancer aged
<70 years.28 For our study, the number of neoadjuvant treated
patients was too low and follow-up since introduction in the
Netherlands was too short to make reliable conclusions. In future
research, it would be interesting to evaluate the impact of time to
treatment on survival in patients with TNBC.
Our study has several limitations. First, we could only adjust
for confounding by indication of measured and known vari-
ables, but several unknown as well as unmeasured confounders
could inﬂuence the outcomes. For instance, the absence of
information regarding the reason for the delayed TTC limits
the interpretation of the association. There are several valid rea-
sons that could delay TTC rather than being poor quality of
delivered care which are associated with worse overall survival,
such as complications due to the surgery, poor physical health,
ECOG performance status or comorbidities that do not allow
timelier initiation of chemotherapy. This information is not
registered in the NCR database and could therefore not be
included in our analyses, but might inﬂuence results if distrib-
uted differently between patient groups or time intervals.
Comorbidity was only registered for a small percentage of the
current population that this factor, unfortunately, could not be
analyzed. Second, the results of the current study need to be
evaluated in a large cohort including additional information
regarding the chemotherapy type, dose, number of cycles and
rate of completion as these are known to inﬂuence survival.
This information was not included in the current overall ana-
lyses, as the type of chemotherapy is considered incomplete in
the NCR before 2011. Nonetheless, analysis of a subgroup of
patients treated between 2011 and 2014 while adjusting for type
of chemotherapy (anthracycline, taxanes or a combination of
both; data not shown), both for patients who underwent BCS
and mastectomy, revealed similar results even despite the short
follow-up. A strength of the present study is both its sample
size, stratiﬁed analyses by type of surgery and strong methodol-
ogy to reduce confounding by indication given the impossibility
to randomize patients by TTC.
Conclusions
The current results suggest that the initiation of chemotherapy
beyond 30 days is associated with decreased overall survival in
TNBC patients who underwent BCS. However, no association
was observed for those who underwent mastectomy. These
results suggest timelier initiation of chemotherapy in TNBC
patients is warranted after BCS.
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